ATE458047T1 - Verfahren zur verstärkung der oligonucleotid- vermittelten nucleinsäuresequenzänderung unter verwendung von zusammensetzungen mit einem hydroxyharnstoff - Google Patents

Verfahren zur verstärkung der oligonucleotid- vermittelten nucleinsäuresequenzänderung unter verwendung von zusammensetzungen mit einem hydroxyharnstoff

Info

Publication number
ATE458047T1
ATE458047T1 AT03716412T AT03716412T ATE458047T1 AT E458047 T1 ATE458047 T1 AT E458047T1 AT 03716412 T AT03716412 T AT 03716412T AT 03716412 T AT03716412 T AT 03716412T AT E458047 T1 ATE458047 T1 AT E458047T1
Authority
AT
Austria
Prior art keywords
hydroxyurea
nucleic acid
acid sequence
compositions containing
sequence change
Prior art date
Application number
AT03716412T
Other languages
English (en)
Inventor
Eric Kmiec
Hetal Parekh-Olmedo
Erin Brachman
Original Assignee
Univ Delaware
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Delaware filed Critical Univ Delaware
Application granted granted Critical
Publication of ATE458047T1 publication Critical patent/ATE458047T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT03716412T 2002-03-07 2003-03-07 Verfahren zur verstärkung der oligonucleotid- vermittelten nucleinsäuresequenzänderung unter verwendung von zusammensetzungen mit einem hydroxyharnstoff ATE458047T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US36305402P 2002-03-07 2002-03-07
US36334102P 2002-03-07 2002-03-07
US36305302P 2002-03-07 2002-03-07
US41698302P 2002-10-07 2002-10-07
PCT/US2003/007217 WO2003075856A2 (en) 2002-03-07 2003-03-07 Methods, compositions, and kits for enhancing oligonucleotide-mediated nucleic acid sequence alteration using compositions comprising a histone deacetylase inhibitor, lambda phage beta protein, or hydroxyurea

Publications (1)

Publication Number Publication Date
ATE458047T1 true ATE458047T1 (de) 2010-03-15

Family

ID=27808811

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03716412T ATE458047T1 (de) 2002-03-07 2003-03-07 Verfahren zur verstärkung der oligonucleotid- vermittelten nucleinsäuresequenzänderung unter verwendung von zusammensetzungen mit einem hydroxyharnstoff

Country Status (9)

Country Link
US (1) US7566535B2 (de)
EP (1) EP1490013B1 (de)
JP (1) JP2005518817A (de)
AT (1) ATE458047T1 (de)
AU (1) AU2003220119A1 (de)
CA (1) CA2478479A1 (de)
DE (1) DE60331297D1 (de)
IL (1) IL163875A0 (de)
WO (1) WO2003075856A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI319387B (en) 2002-04-05 2010-01-11 Astrazeneca Ab Benzamide derivatives
US20070072815A1 (en) * 2004-05-04 2007-03-29 Kmiec Eric B Methods and kits to increase the efficiency of oligonucleotide-directed nucleic acid sequence alteration
AU2009292297B2 (en) 2008-09-11 2014-03-06 Keygene N.V. Method for diagnostic marker development
US8993328B2 (en) * 2008-09-22 2015-03-31 Rutgers, The State University Of New Jersey Media conditioning for improving gene delivery efficiency to differentiating embryonic stem cells
EP3139909B1 (de) 2014-05-09 2025-01-01 Yale University Mit hyperverzweigtem polyglycerin beschichtete partikeln
US11918695B2 (en) 2014-05-09 2024-03-05 Yale University Topical formulation of hyperbranched polymer-coated particles
US12359197B2 (en) 2014-12-12 2025-07-15 Etagen Pharma, Inc. Compositions and methods for editing nucleic acids in cells utilizing oligonucleotides
EP3237908B1 (de) * 2014-12-22 2026-04-22 Universität Zürich Gerichtete evolution von membranproteinen in eukaryotischen zellen mit zellwand
EP3416976A2 (de) 2016-02-16 2018-12-26 Yale University Zusammensetzungen zur verbesserung von gezielter geneditierung und verfahren zur verwendung davon
EP3568470B1 (de) * 2017-01-10 2022-07-06 Christiana Care Health Services, Inc. Verfahren zur stellengerichteten in-vitro-mutagenese unter verwendung von gen-editing-technologien
US20200113821A1 (en) 2017-04-04 2020-04-16 Yale University Compositions and methods for in utero delivery
CN114222813A (zh) * 2019-07-08 2022-03-22 生命技术公司 用于增强细胞培养的组合物和方法
WO2021207673A1 (en) * 2020-04-09 2021-10-14 The Regents of the University of Colorodo, a body corporate Compositions, methods and uses for production of hematopoietic stem cells (hscs)
CN116396865A (zh) * 2023-02-23 2023-07-07 清华大学 一株稳定高表达外源基因的莱茵衣藻突变株及其构建方法

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US217377A (en) * 1879-07-08 hislop
US143052A (en) * 1873-09-23 Improvement in flexible vertically-extensible attachments for boats
US51270A (en) * 1865-11-28 Improvement in children s bedclothes-retainers
US119570A (en) * 1871-10-03 Improvement in coopers crozes and howels
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5955363A (en) 1990-01-03 1999-09-21 Promega Corporation Vector for in vitro mutagenesis and use thereof
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
US6136601A (en) 1991-08-21 2000-10-24 Epoch Pharmaceuticals, Inc. Targeted mutagenesis in living cells using modified oligonucleotides
US5962426A (en) 1993-06-25 1999-10-05 Yale University Triple-helix forming oligonucleotides for targeted mutagenesis
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
CN1048254C (zh) 1993-12-09 2000-01-12 托马斯杰弗逊大学 用于将预定的改变引入靶基因中的化合物
US5604090A (en) 1994-06-06 1997-02-18 Fred Hutchinson Cancer Research Center Method for increasing transduction of cells by adeno-associated virus vectors
US5780296A (en) 1995-01-17 1998-07-14 Thomas Jefferson University Compositions and methods to promote homologous recombination in eukaryotic cells and organisms
JP3770333B2 (ja) 1995-03-15 2006-04-26 大日本住友製薬株式会社 組換えｄｎａウイルスおよびその製造方法
US5776744A (en) 1995-06-07 1998-07-07 Yale University Methods and compositions for effecting homologous recombination
US5912340A (en) 1995-10-04 1999-06-15 Epoch Pharmaceuticals, Inc. Selective binding complementary oligonucleotides
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US6025155A (en) 1996-04-10 2000-02-15 Chromos Molecular Systems, Inc. Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US5760012A (en) 1996-05-01 1998-06-02 Thomas Jefferson University Methods and compounds for curing diseases caused by mutations
US5888983A (en) 1996-05-01 1999-03-30 Thomas Jefferson University Method and oligonucleobase compounds for curing diseases caused by mutations
US5731181A (en) 1996-06-17 1998-03-24 Thomas Jefferson University Chimeric mutational vectors having non-natural nucleotides
WO1997047307A1 (en) 1996-06-14 1997-12-18 The Uab Research Foundation Use of histone deacetylase inhibitors to activate transgene expression
US5928638A (en) 1996-06-17 1999-07-27 Systemix, Inc. Methods for gene transfer
US6057102A (en) 1996-08-08 2000-05-02 The Aaron Diamond Aids Research Center HIV coreceptor mutants
US6043060A (en) 1996-11-18 2000-03-28 Imanishi; Takeshi Nucleotide analogues
AU6432598A (en) 1996-12-12 1998-07-03 Julianna Lisziewicz Materials and methods for gene transfer
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6043389A (en) 1997-03-11 2000-03-28 Mor Research Applications, Ltd. Hydroxy and ether-containing oxyalkylene esters and uses thereof
US6387673B1 (en) 1997-05-01 2002-05-14 The Salk Institute For Biological Studies Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds
AUPO721997A0 (en) 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
US6821759B1 (en) * 1997-06-23 2004-11-23 The Rockefeller University Methods of performing homologous recombination based modification of nucleic acids in recombination deficient cells and use of the modified nucleic acid products thereof
CA2303299C (en) 1997-09-12 2016-02-23 Exiqon A/S Oligonucleotide analogues
US6262116B1 (en) 1998-01-23 2001-07-17 Sloan-Kettering Institute For Cancer Research Transcription therapy for cancers
US6004804A (en) 1998-05-12 1999-12-21 Kimeragen, Inc. Non-chimeric mutational vectors
US6010907A (en) 1998-05-12 2000-01-04 Kimeragen, Inc. Eukaryotic use of non-chimeric mutational vectors
TR200101049T2 (tr) 1998-10-13 2002-01-21 Fujisawa Pharmaceutical Co. Ltd. Siklik tetrapeptid bileşiği ve kullanımı
EP1129175A2 (de) 1998-10-16 2001-09-05 Novartis AG Förderung der selbsterneuerungsaktivität und verbesserte gentransduktion in hematopoietischen stammzellen durch inhibierung des histon-deacetylases
JP2002528088A (ja) 1998-10-28 2002-09-03 ユニバーシティ オブ ワシントン パルボウイルスベクターによる標的化遺伝子修飾
JP2002538348A (ja) 1999-02-24 2002-11-12 ナムローゼ・フェンノートシャップ・ケマ 液体燃料を燃焼させるための燃焼ユニット及び該燃焼ユニットを含む動力生成システム
CZ20013103A3 (cs) 1999-03-02 2002-01-16 The Liposome Company, Inc. Způsob zapouzdřování bioaktivních komplexů do liposomů
JP4269041B2 (ja) 1999-03-02 2009-05-27 国立大学法人九州工業大学 新規な環状テトラペプチド誘導体とその医薬用途
EP2199392A3 (de) * 1999-03-04 2010-12-15 Revivicor, Inc. Genetische veränderung von somatischen zellen und deren verwendungen
EP1161439B1 (de) 1999-03-18 2010-04-21 Exiqon A/S Xylo-lna analoge
WO2000071703A2 (en) 1999-05-03 2000-11-30 Methylgene Inc. Inhibition of histone deacetylase
NZ514348A (en) 1999-05-04 2004-05-28 Exiqon As L-ribo-LNA analogues
WO2001000788A2 (en) 1999-06-25 2001-01-04 Northwestern University Compositions, kits, and methods for modulating survival and differentiation of multi-potential hematopoietic progenitor cells
JP2001064177A (ja) 1999-08-16 2001-03-13 Schering Ag ベンズアミド誘導体を有効成分とする製剤
US6271360B1 (en) 1999-08-27 2001-08-07 Valigen (Us), Inc. Single-stranded oligodeoxynucleotide mutational vectors
JP2001081031A (ja) 1999-08-30 2001-03-27 Schering Ag 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
WO2001018045A1 (en) 1999-09-08 2001-03-15 Sloan-Kettering Institute For Cancer Research Crystal structure of a deacetylase and inhibitors thereof
MXPA02002505A (es) 1999-09-08 2004-09-10 Sloan Kettering Inst Cancer Nueva clase de agentes de citodiferenciacion e inhibidores de histona desacetilasa y metodos de utilizacion de los mismos.
AR025996A1 (es) 1999-10-07 2002-12-26 Valigen Us Inc Plantas no transgenicas resistentes a los herbicidas.
CA2391129A1 (en) 1999-11-10 2001-05-17 The Uab Research Foundation Lentiviral vector transduction of hematopoietic stem cells
CA2391952C (en) 1999-11-23 2012-01-31 Methylgene Inc. Inhibitors of histone deacetylase
CA2394653A1 (en) 2000-01-05 2001-07-12 Novartis Ag Hydrogels
AU2001248701A1 (en) 2000-03-24 2001-10-03 Methylgene, Inc. Inhibitors of histone deacetylase
US6936467B2 (en) 2000-03-27 2005-08-30 University Of Delaware Targeted chromosomal genomic alterations with modified single stranded oligonucleotides
NZ521698A (en) 2000-03-27 2004-08-27 Univ Delaware Targeted chromosomal genomic alterations with modified single stranded oligonucleotides
EP1170008A1 (de) 2000-07-07 2002-01-09 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Valproinsäure und dessen Derivate als Inhibitoren der Histone deacetylase
ATE425177T1 (de) 2000-07-17 2009-03-15 Astellas Pharma Inc Reduziertes fk228 und seine verwendung
WO2002010364A2 (en) 2000-07-27 2002-02-07 University Of Delaware Methods for enhancing targeted gene alteration using oligonucleotides
AU8337701A (en) * 2000-08-14 2002-02-25 Us Health Enhanced homologous recombination mediated by lambda recombination proteins
WO2002026967A2 (en) 2000-09-25 2002-04-04 Thomas Jefferson University Targeted gene correction by single-stranded oligodeoxynucleotides
US7312247B2 (en) 2001-03-27 2007-12-25 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors

Also Published As

Publication number Publication date
EP1490013A2 (de) 2004-12-29
WO2003075856A2 (en) 2003-09-18
DE60331297D1 (de) 2010-04-01
EP1490013B1 (de) 2010-02-17
JP2005518817A (ja) 2005-06-30
AU2003220119A1 (en) 2003-09-22
EP1490013A4 (de) 2005-12-28
WO2003075856A3 (en) 2004-06-24
CA2478479A1 (en) 2003-09-18
US20030207451A1 (en) 2003-11-06
IL163875A0 (en) 2005-12-18
US7566535B2 (en) 2009-07-28

Similar Documents

Publication Publication Date Title
DE60331297D1 (de) Verfahren zur verstärkung der oligonucleotid-vermittelten nucleinsäuresequenzänderung unter verwendung von zusammensetzungen mit einem hydroxyharnstoff
ATE336583T1 (de) Antagonisten auf rezeptorgrundlage und verfahren zur deren herstellung und verwendung
DE59712890D1 (de) Neues gen für eine aminosäure-deacetylase mit spezifität für n-acetyl-l-phosphinothricin, ihre isolierung und verwendung
DE69701671D1 (de) Verfahren und zusammenstellungen zur sequenzbestimmung von nukleinsäuremolekulen
DE60326012D1 (de) Verfahren zur Konzentration von Proteinen
ATE531796T1 (de) Verfahren und zusammensetzungen zur verwendung von zinkfinger-endonukleasen zur verbesserung der homologen rekombination
DE602005022830D1 (de) Weniger immunogene bindungsmoleküle
SE0301951D0 (sv) New method
FI961886A0 (fi) Ihmisen Kunitz-tyyppiset proteaasi-inhibiittorit
DE602007009498D1 (de) Neue fluoreszenzproteine und verfahren zur verwendung davon
ATE490314T1 (de) Verfahren zur förderung der homologen rekombination somatischer zellen und verfahren zur konstruktion eines spezifischen antikörpers
DE60333032D1 (de) Screening-verfahren zur identifizierung wirksamer prä-trans-spleissmoleküle
SG155774A1 (en) Method to generate or determine nucleic acid tags corresponding to the terminal ends of dna molecules using sequences analysis of gene expression (terminal sage)
DE60333486D1 (de) Fluoreszenzproteine aus copepoda-spezies und verfahren zur verwendung davon
ATE340257T1 (de) Histonedeacetylase 9
ATE488252T1 (de) Erhöhte transduktion mit abc- transportersubstratenhemmern
DE60320302D1 (de) Verfahren zur identifikation von modulatoren des humanen orexin-2-rezeptors
DE69927400D1 (de) Pge synthase und verfahren und mitteln zur modulation deren aktivität
ATE394360T1 (de) Verfahren zur verminderung von von der verwendung von fluorphosphitkatalysatoren herruehrenden fluoridverunreinigungen
DE60232346D1 (de) Verfahren zur weithin ungestützten verbrennung von petroleumkoks
DE60330564D1 (de) Verfahren und konstrukte zur expression von clostripain mit hoher ausbeute
NO20055210L (no) Inhibitorproteiner av en protease og anvendelse derav
DE60323120D1 (de) Verfahren zur modulierung von cytokininabhängigen vorgängen in einer pflanze mittels b3-domäne-proteinen
DE60326640D1 (de) Rekombinante biotincarboxylasedomänen zur identifizierung von acetyl-coa-carboxylase-inhibitoren
ATE288487T1 (de) Verfahren zur verlängerung der expression eines interessierenden gens unter verwendung von löslichen ctla4 molekülen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties